New Antiarrhythmic Pharmacologic Therapies and Regulatory Issues in Antiarrhythmic Drug Development

New Arrhythmia Technologies

Volumn , Issue , 2007, Pages 1-13

  Ross, Heather M ^a   Kowey, Peter R ^b   Naccarelli, Gerald V ^c  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Antiarrhythmic therapy; Atrial fibrillation; Azimilide; Carvedilol; Dofetilide

Indexed keywords

EID: 84889407990     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470988725.ch1     Document Type: Chapter

References (45)

1. Singh S, Zoble RG, Yellen L et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102: 2385-2390.
2. Greenbaum R, Campbell TJ, Channer KS et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD study (abstract). Circulation 1998; I-633.
3. Mounsey JP, DiMarco JP. Dofetilide. Circulation 2000; 102: 2665-2770.
4. Torp-Pedersen C, Moller M, Bloch-Thomsen PF et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999; 341: 857-865.
5. Pederson OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pederson C (For the Danish Investigations of Arrhythmia and Morality ON Dofetilide Study Group). Efficacy of dofetilide in the treatment of atrial fibrillationflutter in patients with reduced left ventricular function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) substudy. Circulation 2001; 104: 292-296.
6. Prystowsky EN, Freeland S, Branyas NA, Rardon DP, Fogel RI, Padanilam BJ, Rippy JS. Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. J Cardiovasc Electrophysiol 2003; 14: S287-S290.
7. Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: Comparative efficacy and results of trials. Am J Cardiol 2003; 91: 15D-26D.
8. Naccarelli GV, Wolbrette DL, Bhatta L, Khan M, Hynes J, Samii S, Luck J. A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation. J Interv Card Electrophysiol 2003; 9: 215-222.
9. Fuster V, Rydén LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2001; 38: 1231-1265.
10. Pritchett ELC, Page RL, Carlson M, Undesser K, Fava G [For the Rythmol Atrial Fibrillation Trial (RAFT) Investigators.] Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 2003; 92: 941-946.
11. Meinertz T, Lip GYH, Lombardi F et al. (On behalf of the ERAFT Investigators.) Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rythmonorm Atrial Fibrillation Trial (ERAFT) Study). Am J Cardiol 2002; 90: 1300-1306.
12. Cheng J, Niwa R, Kamiya K, Toyama J, Kodama I. Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes. Eur J Pharmacol 1999; 376: 189-201.
13. Karle CA, Kreye VA, Thomas D et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 2001; 49: 361-370.
14. Maltsev VA, Sabbab HN, Undrovinas AI. Down-regulation of sodium current in chronic heart failure: effect of longterm therapy with carvedilol. Cell Mol Life Sci 2002; 59: 1561-1568.
15. Katritsis DG, Panagiotakos DB, Karvouni E et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol 2003; 92: 1116-1119.
16. Merritt JC, Niebaur M, Tarakji K, Hammer D, Mills RM. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol 2003; 92: 735-736.
17. Kanoupakis EM, Manios EG, Mavkaris HE et al. Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation. Am J Cardiol 2004; 94: 659-662.
18. Camm AJ, Savelieva I. Advances in antiarrhythmic drug treatment of atrial fibrillation: Where do we stand now? Heart Rhythm 2004; 1: 244-246.
19. Singh S. Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. J Interv Card Electrophysiol 2004; 10(S1): 71-76.
20. Choudhury A, Lip GY. Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility. Expert Opin Investig Drugs 2004; 13: 841-855.
21. Matyus P, Varga I, Rettegi T et al. Novel antiarrhythmic compounds with combined class IB and class III mode of action. Curr Med Chem 2004; 11: 61-69.
22. Castro A. Bianconi L, Santini M. New antiarrhythmic drugs for the treatment of atrial fibrillation. PACE 2002; 25: 249-259.
23. Weiss JN, Garfinkel A, Chen PS. Novel approaches to identifying antiarrhythmic drugs. Trends Cardiovasc Med 2003; 13: 326-330.
24. Hohnloser, SH. EURIDIS and ADONIS: maintenance of sinus rhythm with dronedarone in patients with atrial fibrillation or flutter. Paper presented at the European Society for Cardiology Congress 2004, 29 Aug.-1 Sep., Munich, Germany.
25. CV Therapeutics. "Tecadenoson (CVT-510)" http://www.cvt.com/prod_atrial.html. Accessed 19 September 2004.
26. Roden DM. Antiarrhythmic drugs: Past, present, and future. PACE 2003; 26: 2340-2349.
27. Hohnloser SH, Dorian P, Straub M, Beckmann K, Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J Am Coll Cardiol 2004; 44: 99-104.
28. Connolly SJ, Schenell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett ELC. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol 2001; 88: 974-979.
29. Page RL. A-STAR and A-COMET trials (abstract). Europace 2002; 3: A-2.
30. Pratt CM, Singh SN, Al-Khalidi HR et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the azimilide postinfarct survival evaluation (ALIVE) trial. J Am Coll Cardiol 2004; 43: 1211-1216.
31. Camm AJ, Karam R, Pratt C. The azimilide post-infarct survival evaluation (ALIVE) trial. Am J Cardiol 1998; 81(6A): 35D-39D.
32. Sun W, Sarma JSM, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart. Comparison with amiodarone. Circulation 1999; 100: 2276-2281.
33. Touboul P, Brugada J, Capucci A, Crijns H, Edvardsson N, Hohnloser S, Radzik D.(on behalf of the DAFNE Investigators). Dronedarone for the prevention of recurrent atrial fibrillation after cardioversion. Results of a randomized placebo-controlled, double-blind, multicenter study (abstract). PACE 2002; 24: 574.
34. Billman GE. RSD-1235. Cardiome. Curr Opin Investig Drugs 2003; 4: 352-354.
35. Tamargo J, Caballero R, Delpon E. (2003) New mechanistic targets for the treatment of atrial fibrillation. In: Papp JP, Straub M, Ziegler D. eds.Atrial Fibrillation: New Therapeutic Concepts. IOS Press, Ohmsa, Amsterdam, 2003: 133-155.
36. Pederson OD, Bagger H, Kober L, Torp-Pedersen C. Trandolopril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380.
37. Madrid AH, Bueno MG, Rebollo JMG et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study. Circulation 2002; 106: 331-336.
38. Kuhlkamp V, Schirdewan A, Stang K et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. J Am Coll Cardiol 2000; 36: 139-146.
39. Khand AU, Rankin AC, Martin W et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003; 42: 1944-1951.
40. Van Noord T, Tieleman RG, Bosker HA et al. Betablockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. Europace 2004; 6: 343-350.
41. Kober L, Bloch-Thomsen PE, Moller M et al. on behalf of the Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Study Group. Effect of dofetilide in patients with recent myocardial infarction and left ventricular dysfunction: results of the DIAMOND-MI study. Lancet 2000; 356: 2052-2058.
42. Anderson JL, Carlquist JF, Horne BD, Muhlestein JB. Cardiovascular pharmacogenomics: current status, future prospects. J Cardiovasc Pharmacol Ther 2003; 8: 71-83.
43. Liu, BA, Juurlink DN. Drugs and the QT interval-caveat doctor. New Eng J Med 2004; 351: 1053-1056.
44. Kowey PR, Levine JH, Herre JM et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92: 3255-3263.
45. Scheinman MM, Levine JH, Cannom DS et al. Doseranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92: 3264-3272